Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Classical zinc-dependent histone deacetylases (HDACs) are a family of 11 enzymes that catalyze the removal of acetyl groups from lysine residues on both histone and non-histone proteins (UniProt, 2024). These enzymes are categorized into three classes based on their homology to yeast proteins: Class I (HDAC1, 2, 3, and 8), Class II (HDAC4, 5, 6, 7, 9, and 10), and Class IV (HDAC11) (NCBI Gene, 2024). By deacetylating histones, they promote a condensed chromatin state, which typically leads to the repression of gene transcription (PubMed: PMC7400110). Beyond epigenetics, they regulate the function of numerous cytoplasmic proteins involved in the cell cycle, apoptosis, and DNA repair (StatPearls: NBK559020). In many cancers, HDACs are overexpressed or aberrantly recruited to promoters, leading to the silencing of tumor suppressor genes (NIH National Cancer Institute, 2023). Pharmacological inhibition of these enzymes has proven effective in treating certain hematological malignancies by inducing cell cycle arrest and programmed cell death (FDA, 2024).
Inhibition of the zinc-dependent catalytic site of HDAC enzymes, preventing the removal of acetyl groups from lysine residues on histones and non-histone proteins, which results in hyperacetylation, chromatin relaxation, and the reactivation of silenced genes (StatPearls, 2023; PubMed: PMC3436371).
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Classical zinc-dependent histone deacetylase (HDAC) (HDAC).